Cormorant Asset Management’s Design Therapeutics DSGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,150,000
| Closed | -$32.4M | – | 55 |
|
|
2023
Q2 | $32.4M | Hold |
5,150,000
| – | – | 1.82% | 12 |
|
|
2023
Q1 | $29.7M | Hold |
5,150,000
| – | – | 1.96% | 15 |
|
|
2022
Q4 | $52.8M | Buy |
5,150,000
+150,000
| +3% | +$1.54M | 3.54% | 7 |
|
|
2022
Q3 | $83.6M | Sell |
5,000,000
-500,000
| -9% | -$8.36M | 5.84% | 3 |
|
|
2022
Q2 | $77M | Buy |
5,500,000
+343,006
| +7% | +$4.8M | 5.82% | 2 |
|
|
2022
Q1 | $83.3M | Sell |
5,156,994
-283,459
| -5% | -$4.58M | 6.39% | 3 |
|
|
2021
Q4 | $116M | Buy |
5,440,453
+75,603
| +1% | +$1.62M | 6.93% | 3 |
|
|
2021
Q3 | $78.8M | Sell |
5,364,850
-50,000
| -0.9% | -$735K | 3.2% | 8 |
|
|
2021
Q2 | $106M | Buy |
5,414,850
+300,000
| +6% | +$5.87M | 3.6% | 5 |
|
|
2021
Q1 | $146M | Buy |
+5,114,850
| New | +$146M | 3.26% | 3 |
|